Literature DB >> 31571152

Treatment of radiation-induced myelopathy with bevacizumab.

G Cañedo1, I Solis2, C González-San Segundo3, L Madero1, A Lassaletta4.   

Abstract

Entities:  

Keywords:  Bevacizumab; Radiation-induced myelopathy; Radionecrosis

Mesh：

Substances：

Year:  2019        PMID： 31571152     DOI： 10.1007/s12094-019-02209-5

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  21 in total

1.  Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends.

Authors:  Marie-Laure Couec; Nicolas André; Estelle Thebaud; Odile Minckes; Xavier Rialland; Nadège Corradini; Isabelle Aerts; Perrine Marec Bérard; Franck Bourdeaut; Pierre Leblond
Journal:  Pediatr Blood Cancer       Date:  2012-01-27       Impact factor: 3.167

2.  Use of normal tissue complication probability models in the clinic.

Authors:  Lawrence B Marks; Ellen D Yorke; Andrew Jackson; Randall K Ten Haken; Louis S Constine; Avraham Eisbruch; Søren M Bentzen; Jiho Nam; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

3.  An analysis of radiation necrosis of the central nervous system treated with bevacizumab.

Authors:  Karen Tye; Herbert H Engelhard; Konstantin V Slavin; M Kelly Nicholas; Steven J Chmura; Young Kwok; Dominic S Ho; Ralph R Weichselbaum; Matthew Koshy
Journal:  J Neurooncol       Date:  2014-02-07       Impact factor: 4.130

4.  Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab.

Authors:  Wafik Zaky; Michael Wellner; Robert J Brown; Stefan Blüml; Jonathan L Finlay; Girish Dhall
Journal:  Pediatr Hematol Oncol       Date:  2013-10       Impact factor: 1.969

5.  Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.

Authors:  Victor A Levin; Luc Bidaut; Ping Hou; Ashok J Kumar; Jeffrey S Wefel; B Nebiyou Bekele; Jai Grewal; Sujit Prabhu; Monica Loghin; Mark R Gilbert; Edward F Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-01       Impact factor: 7.038

6.  Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.

Authors:  Audrey Hochart; Vianney Gaillard; Marc Baroncini; Nicolas André; Jean-Pierre Vannier; Matthieu Vinchon; Frederique Dubrulle; Jean-Paul Lejeune; Christophe Vincent; Véronique Nève; Héléne Sudour Bonnange; Nicolas Xavier Bonne; Pierre Leblond
Journal:  J Neurooncol       Date:  2015-05-29       Impact factor: 4.130

7.  Effect of bevacizumab on radiation necrosis of the brain.

Authors:  Javier Gonzalez; Ashok J Kumar; Charles A Conrad; Victor A Levin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-02-01       Impact factor: 7.038

Review 8.  Epidemiology and management options for colorectal cancer in children.

Authors:  Raya Saab; Wayne L Furman
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

9.  Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection.

Authors:  Gregory K Friedman; Susan E Spiller; D Keith Harrison; John B Fiveash; Alyssa T Reddy
Journal:  J Pediatr Hematol Oncol       Date:  2013-04       Impact factor: 1.289

10.  Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy.

Authors:  Jeremy D Ruben; Michael Dally; Michael Bailey; Robin Smith; Catriona A McLean; Pasqual Fedele
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-03-06       Impact factor: 7.038
View more
  1 in total

Review 1.  Radiation myelopathy following stereotactic body radiation therapy for spine metastases.

Authors:  Wee Loon Ong; Shun Wong; Hany Soliman; Sten Myrehaug; Chia-Lin Tseng; Jay Detsky; Zain Husain; Pejman Maralani; Lijun Ma; Simon S Lo; Arjun Sahgal
Journal:  J Neurooncol       Date:  2022-06-23       Impact factor: 4.506
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.